Health Secretary RFK Jr. has sparked controversy with new policies encouraging doctors to deprescribe antidepressants, prompting anxiety among psychiatrists at the American Psychiatric Association's annual meeting. The initiative aims to promote appropriate psychiatric prescribing and drive deprescribing when clinically indicated.

The move affects a massive patient population, with 16.6% of U.S. adults currently taking SSRIs. Many physicians worry Kennedy's statements will cause patients to refuse or quit medications prematurely, potentially leading to relapse. The APA's chief executive declared the organization would never support governmental interference in medical practice.

Despite concerns, field leaders are engaging cautiously with the initiative. The APA president will join a Department of Health and Human Services panel developing clinical guidance on tapering antidepressants. Younger psychiatrists, who grew up taking these medications themselves, appear more open to reevaluating prescribing practices.

The pharmaceutical industry faces potential disruption as the nation reexamines its relationship with psychiatric medications. While HHS insists it's not banning SSRIs, the policy shift signals changing attitudes toward mental health treatment that could reshape prescribing patterns nationwide.